{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:37:01Z","timestamp":1791283021393,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T00:00:00Z","timestamp":1454630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T00:00:00Z","timestamp":1454630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glioblastoma is an aggressive, invasive tumor of the central nervous system (CNS). There is a widely acknowledged need for anti-invasive therapeutics to limit glioblastoma invasion. BKM-120 is a CNS-penetrant pan-class I phosphatidyl-inositol-3 kinase (PI3K) inhibitor in clinical trials for solid tumors, including glioblastoma. We observed that BKM-120 has potent anti-invasive effects in glioblastoma cell lines and patient-derived glioma cells <jats:italic>in vitro<\/jats:italic>. These anti-migratory effects were clearly distinguishable from cytostatic and cytotoxic effects at higher drug concentrations and longer durations of drug exposure. The effects were reversible and accompanied by changes in cell morphology and pronounced reduction in both cell\/cell and cell\/substrate adhesion. <jats:italic>In vivo<\/jats:italic> studies showed that a short period of treatment with BKM-120 slowed tumor spread in an intracranial xenografts. GDC-0941, a similar potent and selective PI3K inhibitor, only caused a moderate reduction in glioblastoma cell migration. The effects of BKM-120 and GDC-0941 were indistinguishable by <jats:italic>in vitro<\/jats:italic> kinase selectivity screening and phospho-protein arrays. BKM-120 reduced the numbers of focal adhesions and the velocity of microtubule treadmilling compared with GDC-0941, suggesting that mechanisms in addition to PI3K inhibition contribute to the anti-invasive effects of BKM-120. Our data suggest the CNS-penetrant PI3K inhibitor BKM-120 may have anti-invasive properties in glioblastoma.<\/jats:p>","DOI":"10.1038\/srep20189","type":"journal-article","created":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T10:36:37Z","timestamp":1454668597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma"],"prefix":"10.1038","volume":"6","author":[{"given":"Maria-Carmela","family":"Speranza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal O.","family":"Nowicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajna","family":"Behera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choi-Fong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Antonio","family":"Chiocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean E.","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,5]]},"reference":[{"key":"BFsrep20189_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-pathol-011110-130324","volume":"9","author":"TF Cloughesy","year":"2013","unstructured":"Cloughesy, T. F., Cavenee, W. K. & Mischel, P. S. Glioblastoma: From Molecular Pathology to Targeted Treatment. Annu Rev Pathol. 9, 1\u201325 (2013).","journal-title":"Annu Rev Pathol."},{"key":"BFsrep20189_CR2","first-page":"1","volume":"16","author":"QT Ostrom","year":"2014","unstructured":"Ostrom, Q. T. et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007\u20132011. Neurooncol. 16, 1\u201363 (2014).","journal-title":"Neurooncol."},{"key":"BFsrep20189_CR3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u201396 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep20189_CR4","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1158\/1078-0432.CCR-13-0051","volume":"9","author":"JH McCarty","year":"2013","unstructured":"McCarty, J. H. Glioblastoma resistance to anti-VEGF therapy: Has the challenge been MET? Clin. Cancer Res. 9, 1631\u201333 (2013).","journal-title":"Clin. Cancer Res."},{"key":"BFsrep20189_CR5","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1101\/gad.187922.112","volume":"15","author":"GP Dunn","year":"2012","unstructured":"Dunn, G. P. et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 15, 756\u201384 (2012).","journal-title":"Genes Dev."},{"key":"BFsrep20189_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/neuonc\/nos117","volume":"14","author":"PY Wen","year":"2012","unstructured":"Wen, P. Y., Lee, E. Q., Reardon, D. A., Ligon, K. L. & Alfred Yung, W. K. Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 14, 819\u201329 (2012).","journal-title":"Neuro Oncol."},{"key":"BFsrep20189_CR7","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s10637-014-0082-9","volume":"32","author":"J Rodon","year":"2014","unstructured":"Rodon, J. et al. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest. New Drugs. 32, 670\u201381 (2014).","journal-title":"Invest. New Drugs."},{"key":"BFsrep20189_CR8","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell. 155, 462\u201377 (2013).","journal-title":"Cell."},{"key":"BFsrep20189_CR9","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1186\/1471-2407-14-718","volume":"14","author":"FE Bleeker","year":"2014","unstructured":"Bleeker, F. E. et al. Mutational profiling of kinases in glioblastoma. BMC Cancer. 14, 718 (2014)","journal-title":"BMC Cancer."},{"key":"BFsrep20189_CR10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00432-014-1594-6","volume":"140","author":"PR Wachsberger","year":"2014","unstructured":"Wachsberger, P. R. et al. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma. J. Cancer Res. Clin. Oncol. 140, 573\u201382 (2014).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"BFsrep20189_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/1078-0432.CCR-11-1558","volume":"18","author":"D Koul","year":"2012","unstructured":"Koul, D. et al. Antitumor activity of NVP-BKM120-A selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin. Cancer Res. 18, 184\u201395 (2012)","journal-title":"Clin. Cancer Res."},{"key":"BFsrep20189_CR12","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1158\/1535-7163.MCT-11-1021","volume":"11","author":"SM Brachmann","year":"2012","unstructured":"Brachmann, S. M. et al. Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations. Mol Cancer Ther. 11, 1747\u201357 (2012).","journal-title":"Mol Cancer Ther."},{"key":"BFsrep20189_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1042\/BC20080079","volume":"101","author":"RJ Cain","year":"2009","unstructured":"Cain, R. J. & Ridley, A. J. Phosphoinositide 3-kinases in cell migration. Biol. Cell. Biol. 101, 13\u201329 (2009).","journal-title":"Biol. Cell. Biol."},{"key":"BFsrep20189_CR14","doi-asserted-by":"publisher","first-page":"8644","DOI":"10.1073\/pnas.1221478110","volume":"110","author":"P Mao","year":"2013","unstructured":"Mao, P. et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci USA 110, 8644\u20139 (2013).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep20189_CR15","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1158\/0008-5472.CAN-10-3026","volume":"71","author":"SP Williams","year":"2011","unstructured":"Williams, S. P. et al. Indirubins decrease glioma invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments. Cancer Res. 71, 5374\u201380 (2011).","journal-title":"Cancer Res."},{"key":"BFsrep20189_CR16","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1215\/15228517-2008-041","volume":"10","author":"MO Nowicki","year":"2008","unstructured":"Nowicki, M. O. et al. Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. Neuro. Oncol. 10, 690\u20139 (2008).","journal-title":"Neuro. Oncol."},{"key":"BFsrep20189_CR17","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/neuonc\/not055","volume":"15","author":"P Peruzzi","year":"2013","unstructured":"Peruzzi, P. et al. MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells. Neuro Oncol. 15, 1212\u201324 (2013).","journal-title":"Neuro Oncol."},{"key":"BFsrep20189_CR18","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1593\/neo.11612","volume":"13","author":"PA Agudelo-Garcia","year":"2011","unstructured":"Agudelo-Garcia, P. A. et al. Glioma Cell Migration on Three-dimensional Nanofiber Scaffolds Is Regulated by Substrate Topography and Abolished by Inhibition of STAT3 Signaling 1,2. Neoplasia. 13, 831\u201340 (2011).","journal-title":"Neoplasia."},{"key":"BFsrep20189_CR19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","volume":"22","author":"RS Shannon","year":"2008","unstructured":"Shannon, R. S., Minakshi, N. & Nihal, A. Dose translation from animal to human studies revisited. FASEB J. 22, 659\u2013661 (2008).","journal-title":"FASEB J."},{"key":"BFsrep20189_CR20","unstructured":"Center for Drug Evaluation and Research & Center for Biologics Evaluation and Research. Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers. U.S. Food and Drug Administration Rockville, Maryland, USA (2002)."},{"key":"BFsrep20189_CR21","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1021\/jm800295d","volume":"51","author":"AJ Folkes","year":"2008","unstructured":"Folkes, A. J. et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 51, 5522\u201332 (2008).","journal-title":"J. Med. Chem."},{"key":"BFsrep20189_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/1078-0432.CCR-14-0947","volume":"21","author":"D Sarker","year":"2015","unstructured":"Sarker, D. et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 21, 77\u201386 (2015).","journal-title":"Clin Cancer Res."},{"key":"BFsrep20189_CR23","doi-asserted-by":"publisher","first-page":"12769","DOI":"10.18632\/oncotarget.2646","volume":"5","author":"R Berges","year":"2014","unstructured":"Berges, R. et al. End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca -alkaloids in vitro and in vivo. Oncotarget. 5, 12769\u201387 (2014).","journal-title":"Oncotarget."},{"key":"BFsrep20189_CR24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ceb.2005.08.010","volume":"17","author":"MH Ginsberg","year":"2005","unstructured":"Ginsberg, M. H., Partridge, A. & Shattil, S. J. Integrin regulation. Curr. Opin. Cell Biol. 17, 509\u201316 (2005).","journal-title":"Curr. Opin. Cell Biol."},{"key":"BFsrep20189_CR25","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nrc3792","volume":"14","author":"FJ Sulzmaier","year":"2014","unstructured":"Sulzmaier F. J., Jean, C. & Schlaepfer D. D. FAK in cancer: mechanistic findings and clinical applications. Nat. Rev. Cancer. 14, 598\u2013610 (2014).","journal-title":"Nat. Rev. Cancer."},{"key":"BFsrep20189_CR26","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1158\/0008-5472.CAN-14-1428","volume":"75","author":"M Robertson-Tessi","year":"2015","unstructured":"Robertson-Tessi, M., Gillies, R. J., Gatenby, R. A. & Anderson A. R. Impact of metabolic heterogeneity on tumor growth, invasion and treatment outcomes. Cancer Res. 75, 1567\u201379 (2015).","journal-title":"Cancer Res."},{"key":"BFsrep20189_CR27","first-page":"652","volume":"3","author":"R El Meskini","year":"2015","unstructured":"El Meskini, R. et al. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors. Dis. Model. Mech. 3, 652\u201362 (2015).","journal-title":"Dis. Model. Mech."},{"key":"BFsrep20189_CR28","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.devcel.2014.10.025","volume":"31","author":"J Yue","year":"2015","unstructured":"Yue, J. et al. Microtubules regulate focal adhesion dynamics through MAP4K4. Dev. Cell. 31, 572\u201385 (2015).","journal-title":"Dev. Cell."},{"key":"BFsrep20189_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ccr.2008.06.014","volume":"14","author":"ER Zunder","year":"2008","unstructured":"Zunder, E. R., Knight Z. A., Houseman B. T., Apsel, B. & Shokat, K. M. Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell. 14, 80\u201392 (2008).","journal-title":"Cancer Cell."},{"key":"BFsrep20189_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.canlet.2010.08.014","volume":"298","author":"M Ahluwalia","year":"2010","unstructured":"Ahluwalia, M., Groot, J., Liu, W. & Gladson, C. L. Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies. Cancer Lett. 298, 139\u201349 (2010).","journal-title":"Cancer Lett."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep20189","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep20189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep20189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T13:46:43Z","timestamp":1672840003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep20189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,5]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,4,22]]}},"alternative-id":["BFsrep20189"],"URL":"https:\/\/doi.org\/10.1038\/srep20189","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,5]]},"assertion":[{"value":"24 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20189"}}